Interaction between Immunotherapy and Antiangiogenic Therapy for Cancer

Although immunotherapy has led to durable responses in diverse cancers, unfortunately, there has been limited efficacy and clinical response rates due to primary or acquired resistance to immunotherapy. To maximize the potential of immunotherapy, combination therapy with antiangiogenic drugs seems t...

Descripción completa

Detalles Bibliográficos
Autores principales: Furukawa, Koichi, Nagano, Tatsuya, Tachihara, Motoko, Yamamoto, Masatsugu, Nishimura, Yoshihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7504110/
https://www.ncbi.nlm.nih.gov/pubmed/32859106
http://dx.doi.org/10.3390/molecules25173900
Descripción
Sumario:Although immunotherapy has led to durable responses in diverse cancers, unfortunately, there has been limited efficacy and clinical response rates due to primary or acquired resistance to immunotherapy. To maximize the potential of immunotherapy, combination therapy with antiangiogenic drugs seems to be promising. Some phase III trials showed superiority for survival with the combination of immunotherapy and antiangiogenic therapy. In this study, we describe a synergistic mechanism of immunotherapy and antiangiogenic therapy and summarize current clinical trials of these combinations.

Ejemplares similares